Unraveling the Potential of Isorhamnetin as an Adjuvant in Depression Treatment with Escitalopram

Autor: Omar Gammoh, Esam Y. Qnais, Rabaa Y. Athamneh, Bilal Al-Jaidi, Deniz Al-Tawalbeh, Sara Altaber, Abdelrahim Alqudah, Alaa A. A. Aljabali, Murtaza M. Tambuwala
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Current Issues in Molecular Biology, Vol 45, Iss 9, Pp 7668-7679 (2023)
Druh dokumentu: article
ISSN: 1467-3045
1467-3037
DOI: 10.3390/cimb45090484
Popis: Oxidative stress and inflammation are implicated in depression. While selective serotonin reuptake inhibitors (SSRIs) like escitalopram are commonly prescribed as first-line treatments, their inconsistent efficacy and delayed onset of action necessitates the exploration of adjunctive therapies. Isorhamnetin, a flavonol, has shown antioxidant and anti-inflammatory properties that makes exploring its antidepressant effect attractive. This study aims to investigate the adjuvant potential of isorhamnetin in combination with escitalopram to enhance its antidepressant efficacy in a lipopolysaccharide (LPS)-induced depression model using Swiss albino mice. Behavioral paradigms, such as the forced swim test and open field test, were employed to assess depressive symptoms, locomotion, and sedation. Additionally, enzyme-linked immunosorbent assays were utilized to measure Nrf2, BDNF, HO-1, NO, and IL-6 levels in the prefrontal cortex and hippocampus. The results demonstrate that isorhamnetin significantly improves the antidepressant response of escitalopram, as evidenced by reduced floating time in the forced swim test. Moreover, isorhamnetin enhanced antidepressant effects of escitalopram and effectively restored depleted levels of Nrf2, BDNF, and HO-1 in the cortex caused by LPS-induced depression. Isorhamnetin shows promise in enhancing the efficacy of conventional antidepressant therapy through antioxidant and anti-inflammatory effects.
Databáze: Directory of Open Access Journals
Externí odkaz: